Session Chair Profile

Ph.D., CSO, OX2 Therapeutics and Assistant Professor, University of Minnesota
Biography

Dr. Olin is an Assistant Professor in the Department of Pediatrics, Division of Hematology/Oncology. Dr. Olin graduated from the University of Minnesota, Duluth, in 1995 with a BS in biochemistry and Hydrogeology, a BA in chemistry. After graduating, he worked in industry for 5 years before returning to the U of M to complete his PhD in Veterinary Medicine (Infectious Disease) in 2005. From 2006-2008 Dr. Olin did a postdoctoral fellowship studying the effects of opioids on tuberculosis meningitis, and from 2008-2011 he did a second post doctoral fellowship in brain tumor immunotherapy. Dr. Olin joined the Department of Pediatrics Faculty as an Assistant Professor in 2011. In 2016, Dr. Olin opened a pharmaceutical company OX2 Therapeutics, to raise capital allowing him to develop and test his novel CD200 inhibitor.

Immunotherapy Showcase: OX2 Therapeutics
OX2 Therapeutics was established in 2016 in order to make a transformative impact in the treatment of Primary Brain Tumors.

Targeting The CD200 Immune Checkpoint For Cancer Immunotherapy
OX2 Therapeutics discovered the molecular connection between the CD200, PD-1 and CTLA4 check-points. We demonstrated our CD200 peptide ligand induced cytokine production and up-regulates CD80/86 and MHC-II. In addition, the CD200-ligand overpowered CD200 and PD-L1 immunosuppression, downregulated PD-1 on antigen-presenting and T-cells and down-regulated PD-L1 on antigen-presenting cells inhibiting CTLA4 upregulation.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

Here is your coupon code: newsletter-5percentoff-THISWEEKONLY